<code id='E1051C3172'></code><style id='E1051C3172'></style>
    • <acronym id='E1051C3172'></acronym>
      <center id='E1051C3172'><center id='E1051C3172'><tfoot id='E1051C3172'></tfoot></center><abbr id='E1051C3172'><dir id='E1051C3172'><tfoot id='E1051C3172'></tfoot><noframes id='E1051C3172'>

    • <optgroup id='E1051C3172'><strike id='E1051C3172'><sup id='E1051C3172'></sup></strike><code id='E1051C3172'></code></optgroup>
        1. <b id='E1051C3172'><label id='E1051C3172'><select id='E1051C3172'><dt id='E1051C3172'><span id='E1051C3172'></span></dt></select></label></b><u id='E1051C3172'></u>
          <i id='E1051C3172'><strike id='E1051C3172'><tt id='E1051C3172'><pre id='E1051C3172'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:7
          he exterior of the U.S. Capitol building is seen at sunrise
          Sarah Silbiger/Getty Images

          WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

          The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

          advertisement

          • One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
          • Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
          • A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

          The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more
          Insitro, AI biotech unicorn, brings cash, new research to JPM 2024
          Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

          DaphneKoller,earlybiotechAIentrantInsitro'sfounder,CEOandboardmember.CourtesyJerrickMitra/InsitroNew

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Chronically ill young patients struggle to find fertility info

          AdobeIrecentlyturned25.Ishouldbetakingrisks,jet-settingwithotherBarbies,andflouncingaroundintinytops